CombiGene AB (LARK) AI Stock Analysis

• Market Cap: €50.49M
• Dividend Yield: 8.51%
• Average Volume (3M): 41.41K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.07
• Revenue Growth: -94.12%
• EPS Growth: -25.83%
• Country: SE
• Employees: 9
• Sector: Financial
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -0.62
• Shares Outstanding: 19,801,197
• 10 Day Avg. Volume: 70,026
• 30 Day Avg. Volume: 41,406
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: ―

CombiGene AB's overall stock score reflects substantial financial challenges, with declining revenues and negative cash flows being key risks. The technical analysis indicates a neutral trend, but the valuation remains unattractive due to ongoing losses. The lack of earnings call data and corporate events does not provide additional clarity or optimism for the stock's immediate outlook.

CombiGene AB Business Overview & Revenue Model

Company Description

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.

How the Company Makes Money

CombiGene makes money primarily through the development and commercialization of its gene therapy products. The company generates revenue by partnering with larger pharmaceutical companies for the co-development, licensing, and distribution of its therapies. These partnerships often include upfront payments, milestone payments, and royalties on sales. Additionally, CombiGene may secure funding from grants and research collaborations with academic institutions and research organizations, which support the advancement of its therapeutic programs.

CombiGene AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

CombiGene AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LARK, the sentiment is Negative. The current price of 2.35 is below the 20-day moving average (MA) of 2.54, below the 50-day MA of 2.46, and above the 200-day MA of 2.35, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 39.59 is Neutral, neither overbought nor oversold. The STOCH value of 23.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LARK.

CombiGene AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
LARK	52 Neutral	€50.49M	-1.13	―	8.51%	-94.12%	-25.83%
EXPRS2	44 Neutral	kr64.74M	―	-97.11%	―	-13.08%	32.78%
SPRINT	39 Underperform	kr68.37M	―	-136.44%	―	-30.49%	-242.26%
LIDDS	37 Underperform	€7.78M	-1.40	-112.33%	―	―	88.59%
STABL	34 Underperform	kr14.16M	―	-83.38%	―	―	68.74%